By: Written by Armen Gevorgyan, MD From: oncodaily.com Breast cancer is one of the most common cancers in the world, but also one of the most treatable—especially when detected early. Thanks to major advances in surgery, chemotherapy, hormone therapy, targeted therapy, and immunotherapy, more patients are achieving remission and living longer, healthier lives. Understanding the breast cancer remission rate across …
Personalized Medicine Advances with New Tool to Guide Breast Cancer Treatment Choices
By: Naedine Hazell From: yale.ed Yale pathology researchers created a dependable test that precisely measures key proteins found in breast cancer cells that can help oncologists choose the most effective targeted therapies for patients, says a report published July 16 in Precision Oncology, a journal of the American Society of Clinical Oncology. The assay, named Troplex™, was designed to help …
An Embarrassment of Riches in Oncology With Wayward Decision Support: A Recipe for Disaster?
By: Caroline Seymour From: onclive.com The decision support that is currently available to community oncologists has made it tremendously difficult to keep pace with what many consider to be monumental advances in the understanding and management of breast and lung cancers, according to Maurie Markman, MD. He added that the momentum driving drug discovery is unlikely to ease up, leaving …
Advances in Early-Stage Breast Cancer Pull Biology and Biomarkers Into Focus
From: onclive.com As new data emerge in breast cancer, stepping back from the updates and shedding light on the standard practices as they exist in the clinic are crucial approaches to management of the disease. For example, in early-stage, HER2-positive disease, small changes have rapidly improved outcomes for patients regardless of disease burden. With de-escalation strategies allowing for fixed-duration therapy …
Therapeutic Advances Rapidly Expand the Breast Cancer Armamentarium Across Subtypes
By: Courtney Flaherty From: onclive.com An increasing focus on antibody-drug conjugates (ADCs) for HER2-positive breast cancer signals a potential shift in the standard of care (SOC) for this population. Several investigations have also confirmed the efficacy of CDK4/6 inhibitors in the first- and second-line treatment of hormone receptor (HR)–positive, HER2-negative breast cancer. Yet patients with historically poor prognosis require further …
Breast Cancer Advances in 2022 Showcase a Shifting Landscape
By: OncLive Staff From: onclive.com Joseph A. Sparano, MD, highlights practice-changing clinical trials, novel therapies, the evolving treatment landscape, and unmet needs in the field of breast cancer. Data presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in June and simultaneously published in the New England Journal of Medicine from the phase 3 DESTINY-Breast04 trial (NCT03734029) …
Breast Cancer Advances in 2022 Shape CFS Agenda
From: onclive.com Emerging novel therapies, new stratification factors, and sequencing challenges because of the new classifications for patients with breast cancer will be topics of discussion at the 40th Annual Chemotherapy Foundation Symposium® during the breast cancer sessions. Data presented during the 2022 American Society of Clinical Oncology Annual Meeting in June and simultaneously published in the New England Journal …
New approach to breast cancer prevention
Source: Mayo Clinic From: sciencedaily.com A commentary by Mayo Clinic Cancer Center researchers published in the Journal of Clinical Oncology Practice suggests that advances in breast cancer prevention research have resulted in new and innovative opportunities to modify breast cancer risk and potentially reduce breast cancer incidence and mortality. “It is prudent for health care providers to be knowledgeable about …
Perlmutter Cancer Center Radiation Oncologist Works to Minimize Side Effects of Radiation
Source: nyulangone.org As a radiation oncologist, Naamit K. Gerber, MD, associate professor in the Department of Radiation Oncology at NYU Grossman School of Medicine, provides the latest and most advanced treatments to people who have breast cancer and lymphoma. Dr. Gerber is co-director of the Breast Cancer and Hematologic Malignancies Disease Management Groups at NYU Langone Health’s Perlmutter Cancer Center, …